Pfizer’s ABRYSVO Shows Promise as RSV Vaccine for At-Risk Adults: Phase 3 Study Results

Pfizer’s announcement of positive trial results for its RSV vaccine, Abrysvo, in high-risk adults under 60 led to a 3% increase in its stock, while […]

Pfizer’s Plan to Sold Roughly 630 Million Haleon Shares in Consumer Healthcare Shift

Pfizer aims to sell roughly 630 million shares of Haleon, a company created to handle the Consumer Healthcare business jointly owned by GSK and Pfizer. […]